FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

Press/Media

Period	23 Aug 2023

Media coverage

Title	FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression
Media name/outlet	Hatteras Venture Partners
Country/Territory	United States
Date	23/08/23
URL	ct.moreover.com/?a=51616439323&p=1gw&v=1&x=y3kxyJWYTo_EjeF_7u80Vw
Persons	William Roberts